

LETTER-TO-THE-EDITOR

Characterization of Extended-spectrum β -lactamase-producing Clinical Isolates of *Shigella flexneri*

Sir,

Antimicrobial agents are the mainstay of therapy in severe shigellosis. Conventionally, the fluoroquinolones have been the main drugs of choice for the treatment of shigellosis. With the emergence of fluoroquinolone resistance among *Shigella* (1-5), the third-generation cephalosporins have been used for the treatment of severe shigellosis. However, recent reports of resistance to the third-generation cephalosporins from India (6-8) made the selection of antibiotics for empirical therapy, particularly in children, even more complicated. Here, we report the 2 *Shigella flexneri* isolates which were genotypically proven to produce extended-spectrum β -lactamase (ESBL).

The study was undertaken in the Department of Microbiology and Department of Pediatrics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. The three strains described in this study were isolated from the stool samples of paediatric patients coming to JIPMER hospital. One of the strains was isolated from a one-year old child with the manifestations of severe dysentery which had recurred more than three times while the second strain was isolated from a 10-month old infant who had been diagnosed to have acute gastroenteritis mimicking cholera. The stool samples from these children were plated directly onto MacConkey agar, Deoxycholate citrate agar, and Xylose lysine deoxycholate agar as well as into Selenite F broth for enrichment, which was subcultured after 18 hours in the abovementioned plates. The plates were incubated at 37 °C overnight under aerobic conditions. Following incubation, non-lactose-fermenting pale translucent colonies on MacConkey agar and Deoxycholate citrate agar (Himedia, Mumbai, India) and pink translucent colonies on Xylose lysine deoxycholate (Himedia, Mumbai,

India) were selected for the biochemical tests (9). Further confirmation was done by slide agglutination using specific antisera (Denka-Seiken, Tokyo, Japan). Antibiotic susceptibility testing was done by Kirby Bauer method as per Clinical Laboratory Standards Institute (10) against ampicillin (A) 10 μ g, ceftriaxone (Ci) 30 μ g, ciprofloxacin (Cf) 5 μ g, nalidixic acid (Na) 30 μ g, furaxone (Fx) 300 μ g, chloramphenicol (C) 30 μ g, and cotrimoxazole (Co) 25 μ g, which showed that the two strains were resistant to Ci. The MIC for ceftriaxone was determined by agar dilution method and E-test for those strains that were resistant to the drug. For the agar dilution method, ceftriaxone-sodium salt (Himedia, Mumbai, India) was used. Different dilutions of the antibiotics were used as per recommendations (10,11). ATCC *Escherichia coli* 25922 was inoculated on each plate as growth control. The E-test was performed as per the manufacturers' instructions (Biomerieux, India). Both the strains had an MIC value of >256 μ g/mL for ceftiaxone. The ESBL detection was performed by combination disc method on the ceftriaxone-resistant isolates (10,12). These three strains, when phenotypically tested by the combination disc method, were positive for ESBL production. The DNA was extracted from the *Shigella* strains, using the boiling method (13). The DNA was subjected to PCR amplification targeting the known class of ESBL genes, using primers (Table 1) that would identify sequences encoding the ESBL genes TEM, CTX, and SHV.

The Multiplex PCR was done to identify *blaSHV* and *blaCTX-M* genes simultaneously (14). The reaction mixture consisted of 2 μ L of DNA, 100 pmol (1 μ L) concentration of each oligonucleotide primer of *blaSHV*, 30 pmol (1 μ L) concentration of each oligonucleotide primer of *blaCTX*, master mix of 35 μ L containing dNTPs, 1.25 U Taq polymerase and buffer with 1.5 mM MgCl₂, and sterile nuclease-free water of 9 μ L, making a total volume of 50 μ L. The cycling conditions included an initial denaturation step at 94 °C for 5 min and then 32 cycles with denaturation at 94 °C for 45 sec, primer annealing at 50 °C for 40 sec, and extension at 72 °C for 60 sec. A final extension step at 72 °C for 10 min was performed. The reaction mixture consisted of 4 μ L of DNA, 2 μ L of 100 pmol concen-

Correspondence and reprint requests:

Dr. Subhash Chandra Parija
Professor and Head
Department of Microbiology
JIPMER, Puducherry 605 006
India
Email: subhashparija@yahoo.co.in
Fax: 91-413-2296250

Table 1. Primers used in the study for detecting the ESBL genes

Primer	Sequence	Product-size (bp)	Reference
SHV-F	5'ATT TGT CGC TTC TTT ACT CGC-3'	1,018 bp	14
SHV-R	5' TTT ATG GCG TTA CCT TTG ACC-3'		
CTXMU-1	5'ATG TGC AGY ACC AGT AAR GT 3'	544 bp	14
CTXMU-2	5' TGG GTR AAR TAR GTS ACC AGA 3'		
TEM F	5'ATA AAA TTC TTG AAG ACG AAA 3'	1,076 bp	15
TEM R	5'GAC AGT TAC CAA TGC TTA ATC 3'		

tration of each oligonucleotide primer of *bla*TEM, master mix of 10 µL containing dNTPs, 1.25U Taq polymerase and buffer with 1.5 mM MgCl₂, and sterile nuclease-free water of 7 µL, making a total volume of 25 µL. The cycling conditions used were 30 cycles of 94 °C for 1 min, 56 °C for 1 min, and 72 °C for 1 min, with a final extension of 72 °C for 10 min (15). The resulting PCR products were documented on 1.5% agarose gel. PCR sequencing was performed to identify β-lactamase-resistant genes *bla*TEM, *bla*SHV, and *bla*CTX-M. Sequencing of β-lactamase gene amplicons was conducted by the Macrogen Inc., Seoul, Korea. The BLASTN program (www.ncbi.nlm.nih.gov/BLAST) was used for database searching. Using Multiplex PCR for *bla*CTX and *bla*SHV genes, 2 of the strains of *Shigella flexneri* were positive for *bla*CTX gene with a band-size of 544 bp. The sequencing results indicate that, out of both the strains harbouring the plasmid-encoded *bla*CTX genes, one matched the sequence of CTX-M-15 (with 100% identity, AC-FJ997866).

Plasmid DNA extraction was done based on the principle of alkaline lysis method (16). The resulting plasmid DNA was separated in 0.8% agarose gels. The size of the plasmid was determined with a 500 bp ladder and a supercoiled plasmid DNA ladder, ranging from 500 bp to 33.5 kbp (Merck Specialities Private Limited, Bangalore, India). The plasmid profile of the plasmid DNA extracted from these isolates showed bands of 33.5 kbp.

Transformation experiments were performed using *E. coli* J53 strain as recipient previously described (17). For broth-mating studies, 0.1 mL of donors and 0.9 mL recipients (plasmid-free) were inoculated onto BHI broth culture made up to 10 mL volume and incubated at 37 °C for 18 hours. The recipient strain was plated onto LB agar plates supplemented with 6 µg/mL ceftriaxone as control. The transformed *E. coli* colonies were selected on LB agar plates and MacConkey agar plates supplemented with 6 µg/mL of ceftriaxone. Screening was carried out using the standard protocol (18). The transformed identities were reconfirmed based

on their biochemical characters. The transformants were identified in the Blue-White screening agar, and their identities were confirmed with biochemical assays to be *E. coli*. Plasmid from the transformant was extracted, which also showed the same plasmid as that of the donor strain (data not shown).

DISCUSSION

Shigellosis is the major cause of dysentery in children. *S. flexneri* is the most predominating pathogen in developing countries, and the same is reflected in our study also. Antibiotics are indicated in the treatment for shigellosis. However, the alarming rise in antimicrobial resistance is a great threat to mankind. In the recent decades, majority of the members of the family Enterobacteriaceae were shown to produce extended-spectrum β-lactamase. This fact did not spare the genus *Shigella* where an SHV-11 ESBL-producing *S. dysenteriae* strain was reported in India in 1999 (19). There are several other reports of ESBL-producing *Shigella* from India (6-8). Third-generation cephalosporin-resistant *S. flexneri* isolate was first reported from a stool sample of a 16-month old child in Paris in 1995 (20). In the recent years, various ESBL-producing *Shigella* were also reported from Korea (CTX-M-14) (21), Argentina (CTX-M-2) (22), Viet Nam (CTX-M-15 and CTX-M-24) (23), and Turkey (24). In India, CTX-M-3 type of ESBL was reported in *S. sonnei* from Andaman and Nicobar islands (8). A novel CTX-M-64, a hybrid of CTX-M-15 and CTX-M-14, was reported by Nagano *et al.* from a shigellosis patient infected with *S. sonnei* after returning to Japan from China (25).

Conjugation experiments showed the transfer of the plasmid-encoded *bla*CTX-M-15 gene from the ESBL-producing *S. flexneri* isolate to *E. coli* J53. Transconjugants demonstrated resistance to third-generation cephalosporins mediated by transfer of a >35.5 kb plasmid. CTX-M-15 is a major CTX-M subtype which has spread all over the world and has been found in many members of the Enterobacteriaceae (26-28).

Conclusions

Cephalosporins are the antibiotics of choice for severe and hospitalized cases, particularly in children where quinolones are not considered as treatment options by most clinicians. ESBL production in *Shigella* has complicated the situation, limiting the treatment options. Further, *Shigella* has the ability to carry multiple plasmids in relation to virulence and the antimicrobial resistance. In this study, we have described three *Shigella flexneri* strains which were resistant to ceftriaxone and were shown to produce ESBL by phenotypic and molecular methods. The major concern regarding these strains is that these were isolated from the stool samples of the children, in which case, most of the clinicians do not prefer using quinolones and cephalosporins. However, with the emergence of these strains showing resistance to the third-generation cephalosporins, the protocols for therapy of shigellosis need to be re-analyzed with emphasis on close continuous monitoring. This imparts that continued surveillance is needed to identify the ESBL-producers in patients with shigellosis which, in turn, will assist us in developing effective strategies in controlling the current situation.

REFERENCES

1. von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD *et al.* A multicentre study of *Shigella* diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. *PLoS Med* 2006;3:e353.
2. Niyogi SK, Pazhani GP. Multiresistant *Shigella* species isolated from childhood diarrhea cases in Kolkata, India. *Jpn J Infect Dis* 2003;56:33-4.
3. Srinivasa H, Baijayanti M, Raksha Y. Magnitude of drug resistant shigellosis: a report from Bangalore. *Indian J Med Microbiol* 2009;27:358-60.
4. Kosek M, Yori PP, Pan WK, Olortegui MP, Gilman RH, Perez J *et al.* Epidemiology of highly endemic multiply antibiotic-resistant shigellosis in children in the Peruvian Amazon. *Pediatrics* 2008;122:e541-9.
5. Pazhani GP, Niyogi SK, Singh AK, Sen B, Taneja N, Kundu M *et al.* Molecular characterization of multi-drug-resistant *Shigella* species isolated from epidemic and endemic cases of shigellosis in India. *J Med Microbiol* 2008;57(Pt 7):856-63.
6. Mandal J, Mondal N, Mahadevan S, Parija SC. Emergence of resistance to third-generation cephalosporin in *Shigella*—a case report. *J Trop Pediatr* 2010;56:278-9.
7. Varghese SR, Aggarwal A. Extended spectrum beta-lactamase production in *Shigella* isolates—a matter of concern. *Indian J Med Microbiol* 2011;29:76-8.
8. Bhattacharya D, Bhattacharjee H, Ramanathan T, Sudharma SD, Singhanian M, Sugunan AP *et al.* Third-generation cephalosporin resistance in clinical isolate of *Shigella sonnei* in Andaman & Nicobar Islands, India. *J Infect Dev Ctries* 2011;5:674-6.
9. Bopp CA, Ries AA, Wells JG. Laboratory methods for the diagnosis of epidemic dysentery and cholera. Atlanta, GA: Centers for Disease Control and Prevention, 1999. 108 p. (WHO/CDS/CSR/EDC/99.8).
10. Cockerill FR, Wikler MA, Bush K, Dudley MN, Eliopoulos GM, Hardy DJ *et al.* Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2011. 165 p.
11. Jorgensen JH, Turnidge JD. Susceptibility test methods: dilution and disk diffusion methods. In: Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover RC, editors. *Manual of clinical microbiology*. 9th ed. Washington, DC: American Society for Microbiology Press, 2007:1108-27.
12. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β -lactamases conferring transferable resistance to newer β -lactam agents in *Enterobacteriaceae*: hospital prevalence and susceptibility patterns. *Rev Infect Dis* 1988;10:867-78.
13. Bali EB, Açık L, Sultan N. Phenotypic and molecular characterization of SHV, TEM, CTX-M and extended-spectrum β -lactamase produced by *Escherichia coli*, *Acinobacter baumannii* and *Klebsiella* isolates in a Turkish hospital. *Afr J Microbiol Res* 2010;4:650-4.
14. Jemima SA, Verghese S. Multiplex PCR for *bla*(CTX-M) & *bla*(SHV) in the extended spectrum beta lactamase (ESBL) producing gram-negative isolates. *Indian J Med Res* 2008;128:313-7.
15. Kim S, Kim J, Kang Y, Park Y, Lee B. Occurrence of extended-spectrum β -lactamases in members of the genus *Shigella* in the Republic of Korea. *J Clin Microbiol* 2004;42:5264-9.
16. Birnboim HC, Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. *Nucleic Acids Res* 1979;7:1513-23.
17. Shiraki Y, Shibata N, Doi Y, Arakawa Y. *Escherichia coli* producing CTX-M-2 β -lactamase in cattle, Japan. *Emerg Infect Dis* 2004;10:69-75.
18. Sambrook J, Russell DW. *Molecular cloning: a laboratory manual*. 3rd ed. New York, NY: Cold Spring Harbor Laboratory Press, 2001. Chapter 1: protocol 27.
19. Ahamed J, Kundu M. Molecular characterization of the SHV-11 β -lactamase of *Shigella dysenteriae*. *Antimicrob Agents Chemother* 1999;43:2081-3.
20. Fortineau N, Naas T, Gaillot O, Nordmann P. SHV-type extended-spectrum β -lactamase in a *Shigella flexneri*

- clinical isolate. *J Antimicrob Chemother* 2001;47:685-8.
21. Pai H, Choi E-H, Lee H-J, Hong JY, Jacoby GA. Identification of CTX-M-14 extended-spectrum β -lactamase in clinical isolates of *Shigella sonnei*, *Escherichia coli*, and *Klebsiella pneumoniae* in Korea. *J Clin Microbiol* 2001;39:3747-9.
 22. Radice M, González C, Power P, del Carmen Vidal M, Gutkind G. Third-generation cephalosporin resistance in *Shigella sonnei*, Argentina. *Emerg Infect Dis* 2001;7:442-3.
 23. Nhu NTK, Vinh H, Nga TVT, Stabler R, Duy PT, Vien LTM et al. The sudden dominance of blaCTX-M harbouring plasmids in *Shigella* spp. circulating in Southern Vietnam. *PLoS Negl Trop Dis* 2010;4:e702.
 24. Acikgoz ZC, Gulay Z, Bicmen M, Gocer S, Gamberzade S. CTX-M-3 extended-spectrum β -lactamase in a *Shigella sonnei* clinical isolate: first report from Turkey. *Scand J Infect Dis* 2003;35:503-5.
 25. Nagano Y, Nagano N, Wachino J-i, Ishikawa K, Arakawa Y. Novel chimeric β -lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 β -lactamases, found in a *Shigella sonnei* strain resistant to various oxyimino-cephalosporins, including ceftazidime. *Antimicrob Agents Chemother* 2009;53:69-74.
 26. Vien LTM, Baker S, Thao LTP, Tu LTP, Thuy CT, Nga TTT et al. High prevalence of plasmid-mediated quinolone resistance determinants in commensal members of the *Enterobacteriaceae* in Ho Chi Minh city, Vietnam. *J Med Microbiol* 2009;58(Pt 12):1585-92.
 27. Woerther P-L, Angebault C, Jacquier H, Hugede H-C, Janssens A-C, Sayadi S et al. Massive increase, spread, and exchange of extended spectrum β -lactamase-encoding genes among intestinal *Enterobacteriaceae* in hospitalized children with severe acute malnutrition in Niger. *Clin Infect Dis* 2011;53:677-85.
 28. Smet A, Van Nieuwerburgh F, Vandekerckhove TTM, Martel A, Deforce D, Butaye P et al. Complete nucleotide sequence of CTX-M-15-plasmids from clinical *Escherichia coli* isolates: insertional events of transposons and insertion sequences. *PLoS One* 2010;5:e11202.

Jharna Mandal, V. Sangeetha, Nivedithadivya, Ankita Das, Subhash Chandra Parija

Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India